Incliva

Noticias

Hypertension is the risk factor with the greatest impact on metabolic syndrome

INCLIVA INVESTIGACION BIOMEDICINA VALENCIA ESCARVAL HIPERTENSIÓN
40% of deaths in Valencia are caused by a cardiovascular event associated with hypertension. This study was conducted in collaboration with more than 900 Valencian Primary Healthcare professionals who participated in the Valencian Cardiometabolic Study (ESCARVAL). Read more (in Spanish)
Published on 28/04/2016.View more »

INCLIVA leads a clinical trial to evaluate two surgical techniques used in pancreas cancer

 INCLIVA INVESTIGACION BIOMEDICINA VALENCIA CIRUGÍA
Eleven Spanish hospitals are participating. It is one of the few independent surgical research projects of is kind being carried out in Spain. Read more (in Spanish)
Published on 16/02/2016.View more »

INCLIVA and the University of Valencia use fruit flies to analyze the cardiac alterations present in the rare disease...

INCLIVA INVESTIGACIÓN GENETICA CARDIOVASCULAR BIOMEDICINA VALENCIA
Myotonic dystrophy is a rare inherited disease which arises from a genetic alteration affecting muscles. Research has confirmed the efficacy of a compound, pentamidine, with described activity against muscular dystrophy. The muscular dystrophy model flies fed with pentamidine showed a reduction in arrhythmia and improved contractility. Read more (in Spanish)  
Published on 18/01/2016.View more »

INCLIVA joins the EATRIS network

NCLIVA EATRIS INVESTIGACIÓN BIOMEDICINA VALENCIA
EATRIS is the European Advanced Translational Research Infrastructure in Medicine. Read more (in Spanish)
Published on 02/01/2016.View more »